| Kasper ready to write his own chapter
He explains it is Gerd Müller, displaying an encyclopedic knowledge in gushing about the German's World Cup scoring exploits of 1974. He then lifts up his sweatshirt to reveal a T-shirt adorned with Muhammad Ali, before enthusing about the Rumble In The Jungle fight that also took place a full 22 years before his birth. The next enquiry directed towards the 20-year-old concerns the need to be hulking to play in his position. It leads the Dane to rattle off the names and heights of every goalkeeping luminary from the past two decades as proof his 6ft 1in frame is up to the task. It is, indeed, the tale of the tape for a certain Peter Schmeichel, no less. A father and son combination who also share bright blond locks and an ability for measured articulation. For all that he naturally does not want to be seen merely as an extension of his golden goalie old fella, Falkirk's latest imaginative acquisition does not attempt to detach himself from his upbringing.
Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by ...
BOSTON, Nov. 7 /PRNewswire/ -- Ferring Pharmaceuticals presented the results of a cost-utility study supporting the adoption of EUFLEXXA(TM) (1% sodium hyaluronate) intra-articular hyaluronic acid (HA) for the relief of pain in patients with osteoarthritis (OA) of the knee at the American College of Rheumatology's Annual Scientific Meeting in Boston, MA, November 6-11. Using data from a larger trial, the study demonstrated that an intra- articular treatment course of HA (EUFLEXXA(TM)) for knee OA, as compared with non-HA therapy, provides a cost-utility benefit that supports adopting this technology. The data also show that wider adoption of this technology would result in greater financial savings to the health care system. Osteoarthritis is one of the most common diseases seen in the rheumatologist's office, costing the health care system nearly $100 billion per year.
Ferring Pharmaceuticals' EUFLEXXA(TM) Signs on as a Sponsor of the ...
PARSIPPANY, N.J., Aug. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announced today that its hyaluronic acid therapy EUFLEXXA(TM) (1% sodium hyaluronate) will serve as a bronze medal sponsor of the 2007 Huntsman World Senior Games, to be held from October 8 -- October 20 in St. George, Utah. "By sponsoring the Huntsman World Senior Games, we hope to increase public awareness of knee osteoarthritis (OA) and its treatment options, while supporting those who live with the condition every day," said William Garbarini, Executive Director for Sales and Marketing, Orthopedic Business Unit at Ferring. "These Games send an important message about the priceless benefits of staying healthy and keeping active." EUFLEXXA(TM) spokesperson and 1976 Olympic Gold Medal winner Bruce Jenner is an inspiring example of this philosophy.
|
